We are the partner of choice for life sciences teams navigating the most complex questions in oncology evidence generation
-
Natural history and unmet needs
-
Biomarker testing strategy
-
Target Product Profile (TPP) design
-
Trial design and protocol optimization
-
Predictive modeling and digital twins
-
Treatment patterns and survival
-
Cost and resource utilization
-
Natural history and burden of illness
-
Comparative effectiveness
-
Indirect treatment comparisons
-
Clinical decision making analysis
-
Natural history and burden of illness
-
Comparative effectiveness
-
Post-marketing commitments and requirements
-
International transportability
-
HTA submission
-
Risk analysis
-
Fit-for-purpose assessment
-
Response to information request
-
Briefing book composition
-
Health Authority meeting prep and attendance
-
Size market opportunities
-
Launch and market performance
-
HCP segmentation and engagement
-
Prescribing patterns and physician sentiment
Flexible engagement models
As your questions evolve, so do we. From long-term evidence strategy to rapid commercial insights, we act as a force multiplier for your teams, turning complexity into clarity and evidence into confident action.
End-to-end support
Ongoing insights
One-time insights
“Flatiron’s seamless collaborative approach and subject matter knowledge advanced a real-world comparative effectiveness study evaluating treatment-specific sub-cohorts within a broader, real-world biomarker-identified population. Flatiron’s scientific innovation and breadth of analytic capabilities have greatly contributed to generating impactful evidence for this oncology research project.”
WW HEOR Director, Life Science Company
by the numbers
2,000+
peer-reviewed publications
650+
custom service engagements
10+
years experience with FDA and NICE
200+
in-house oncology clinicians, research scientists and data engineers
We pair the right data, AI-powered intelligence, and deep expertise precisely matched to your research questions and evidence needs
Best-in-class data
Our insights are built on 15+ years of oncology RWD with unmatched scale, depth, and timeliness that gives you the trusted clarity to act on your most complex strategic decisions.
Fit-for-purpose AI
Our AI models are developed and validated by in-house oncologists and scientists, so the insights they generate meet the bar for publication, regulatory submission, and commercial decisions.
